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Aims: To compare cardiac function when pacing from the right or left ventricular apex in patients with
preserved left ventricular systolic function, at 1-year follow-up.
Methods: Prospective, multicentre centre randomizing conventional right ventricular apical (RVA) versus
left ventricular apical (LVA) pacing using a coronary sinus lead in patients requiring ventricular pacing for
bradycardia. Follow-up was performed using 3D-echocardiography at 6 and 12 months.
Results: A total of 36 patients (age 75.4 ± 8.7 years, 21 males) were enrolled (17 patients in the RVA
group and 19 patients in the LVA group). A right ventricular lead was implanted in 8 patients in the LVA
group, mainly because of high capture thresholds. There were no differences in the primary endpoint of
LVEF at 1 year (60.4 ± 7.1% vs 62.1 ± 7.2% for the RVA and LVA groups respectively, P ¼ 0.26) nor in any of
the secondary endpoints (left ventricular dimensions, left ventricular diastolic function, right ventricular
systolic function and tricuspid/mitral insufﬁciency). LVEF did not change signiﬁcantly over follow-up in
either group. Capture thresholds were signiﬁcantly higher in the LVA group, and two patients had un-
expected loss of capture of the coronary sinus lead during follow-up.
Conclusions: Left univentricular pacing seems to be comparable to conventional RVA pacing in terms of
ventricular function at up to 1 year follow-up, and is an option to consider in selected patients (e.g. those
with a tricuspid valve prosthesis).
Copyright © 2017, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
It is well established that chronic right ventricular apical (RVA)
pacing may have an adverse effect on left ventricular systolic
function [1,2] leading in the long term to adverse clinical outcome
in such as heart failure [3], atrial ﬁbrillation [4,5], and even death
[6]. As an alternative to RVA pacing, the interventricular septum or
right ventricular outﬂow tract have been proposed to avoid these
adverse effects, but results have been equivocal [7]. In the PACE trial
[2], cardiac resynchronization therapy (CRT) has been shown to
preserve left ventricular ejection fraction (LVEF) compared to an
absolute decrease of 7% at 1 year with RVA pacing in patients with
normal baseline systolic function. However, before CRT implanta-
tion can be routinely proposed in these patients, further evidence is
required to support the ﬁndings and incremental cost related to
CRT implantation compared to a dual chamber device needs to be
addressed. Another alternative is pacing from the left ventricular
apex (LVA), which has shown more favourable results in terms of
left ventricular pump function than the RVA [8,9]. The LVA can be
paced either using a surgically-placed epicardial lead, or trans-
venously via transseptal puncture or the coronary sinus (CS). The
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ﬁrst two alternatives have limitations, as they respectively require
thoracotomy or are associated with a high risk of thrombo-embolic
events [10]. Current implantation tools allow safe and successful
implantation of left ventricular leads in >95% of patients [11].
Furthermore, positioning the left ventricular pacing lead in the
distal anterior cardiac vein is usually technically easier than in a
lateral or postero-lateral branch, without the risk of adverse effects
such as phrenic nerve capture. The approach has the added
advantage, compared to right ventricular pacing, of bypassing the
tricuspid valve, which may prevent valve dysfunction associated
with pacing leads [12].
Our aim was to compare chronic effects on LVEF resulting from
transvenous pacing of the RVA versus the LVA in patients with
preserved left ventricular systolic function.
2. Material and methods
The Right Versus Left Apical transvenous pacing for patients
with preserved left ventricular systolic function (RIVELA) studywas
a physician-initiated multicentre, prospective, randomized, open
label study conducted in Switzerland. Blinding was impossible due
to group attribution being readily assessable by the chest X-ray,
electrocardiogram or echocardiography. Randomization was per-
formed 1:1 using a list of randomly permuted blocks into 2 groups
stratiﬁed by baseline LVEF (/>55%). Patients randomized to the
RVA group had a conventional pacing lead positioned at the RVA
using a standard implantation technique. Those randomized to the
LVA group had dedicated CS lead positioned as close as possible to
the left ventricular apex (see Fig. 1). Inclusion criteria were: age>18
years; requirement for ventricular pacing according to current
guidelines (including chronic atrial ﬁbrillation); anticipated 50%
daily ventricular pacing; LVEF 45% as evaluated by 2D-echocar-
diography, 3D-echocardiography, magnetic resonance imaging or
radionuclide/contrast ventriculography. Patients were excluded it
they had prior tricuspid valve replacement (annuloplasty was
permitted), an intrinsic rhythm <30bpm, permanent atrial ﬁbril-
lation scheduled to undergo ablation of the atrioventricular node,
an echocardiographic window of insufﬁcient quality for measuring
LVEF, life expectancy of <1 year, pregnancy, or were unable/un-
willing to sign a patient informed consent form.
Pacemakers were either dual-chamber (DDDR) or single-
chamber (VVIR) St-Jude Medical (Sylmar, CA) models with the
ventricular autocapture feature. The model of the bipolar right
ventricular pacing lead was left to the discretion of the implanting
physician, and was implanted at the apex according to standard
implantation techniques. The bipolar left ventricular pacing lead
was the St-Jude Medical Quickﬂex model, implanted distally as
closely as possible to the apex e.g. via the anterior cardiac vein or
postero-lateral vein. The CS was cannulated using dedicated guid-
ing catheters as for standard CRT implantation. Programming of
device parameters was left to the discretion of the study centre.
There was no requirement to force ventricular pacing (e.g. by
shortening AV intervals).
An echocardiogram (during ventricular pacing at 80bpm, to
Fig. 1. Examples of patients in the left ventricular apical group. A (left) Coronary sinus venogram showing possible target anterior cardiac and posterior veins with (right) ﬁnal lead
position in the posterior cardiac vein (postero-anterior views). B another patient with the coronary sinus lead in the anterior cardiac vein (postero-anterior and left lateral views).
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avoid changes in LVEF due to different heart rates) was performed
within 72 h of implantation at 6 months and at 12 months' follow-
up. A Philips (Gronigen, NL) iE33 echocardiograph was used for
recording a standard and a real-time 3D echocardiogram (RT3DE).
Two-dimensional, M-Mode, Doppler, tissue Doppler imaging (TDI)
and 2D strain measurements were performed according to rec-
ommendations [13,14]. RT3DE acquisition with a matrix-array
transducer (X3-1 or X5-1) from the apical view was used for
measuring left ventricular end-diastolic (LVEDV) and end-systolic
(LVESV) volumes and LVEF. Raw data were analyzed by an echo-
cardiography core lab at the University Hospital of Geneva by a
single operator (H.M.) using Philips QLAB 9.1.
Device interrogation and clinical assessment were performed at
each follow-up.
The primary endpoint was comparison of LVEF (measured by
RT3DE) between groups at 1 year follow-up. Secondary endpoints
were changes in echocardiographic parameters over time
(including LVEF, LVEDV, LVESV, right ventricular function, severity
of tricuspid and mitral regurgitation, tissue Doppler imaging) and
evolution of pacemaker electrical parameters.
Data were entered on electronic case-report forms with moni-
toring by independent clinical trial units at each centre. The trial
was registered on clinicaltrials.gov as NCT01535404 and conducted
according to the declaration of Helsinki. Approval was obtained by
the institutional ethics committees and each patient provided
written informed consent.
2.1. Statistical analysis
In order to show a difference of 5% (in absolute terms) in LVEF
between groups at 12 months with 90% power, a sample size of 172
patients. (86 in each group) was calculated. Evaluation was per-
formed according to a modiﬁed intention-to-treat principle, with
patients analyzed as initially randomized. No data imputation was
performed for the main analyses, though the analysis of the pri-
mary endpoint was repeated, by conservatively imputing the worst
observed LVEF in the LV group and the best observed LVEF in the RV
group. Data are reported asmean ± standard deviation (SD) and the
Mann Whitney U test and the Fisher exact test, for continuous and
categorical variables respectively, were performed to verify that
baseline characteristics were uniformly distributed. A generalized
linear model was used to compare groups for the primary endpoint,
with a Huber-White robust standard errors analysis to account for
intra-centre correlation. The mean difference and 95% conﬁdence
interval (95%CI) were computed. Mixed models with random effect
for centre and patient, and exchangeable correlation structurewere
used to compare changes over time of continuous echo and device
data. A generalized linear model with identity link was used to
compare rate of adverse events between groups. Two-sided P
values of <0.05 were considered to be statistically signiﬁcant. An-
alyses were performed by a statistician (C.K) using Stata 14.2 (Sta-
taCorp, College Station, TX, USA).
3. Results
A total of 36 patients (17 in the RVA group and 19 in the LVA
group) were enrolled from the 5 centres during the period ranging
from 15.5.2012 to 11.8.2014. Patient demographics are shown in
Table 1. The study was terminated because of slow enrolment, due
logistical challenges, and especially due to the advent of MRI-
conditional devices (randomization to the LVA group precluded
MRI-conditionality). A total of 8/19 (42%) patients randomized to
the LVA group received a right ventricular lead instead. The reasons
were high capture thresholds in 5 patients, CS dissection in 2 pa-
tients and pneumothorax in 1 patient.
Total (skin-to-skin) procedure durations were 41 ± 11min in the
RVA group and 91 ± 34min in the LVA group (P < 0.001); ﬂuoros-
copy durations were 4.6 ± 2.3min versus 18.1 ± 10.4min respec-
tively (P < 0.001). All patients in the RVA group received a lead in
the intended position. In patients in the LVA group who received a
left ventricular lead, the lead was in the anterior cardiac vein in 8
patients (in a mid-ventricular position in 6 patients and in an apical
position in 2 patients) and in a posterior or lateral vein in 3 patients
(in a mid-ventricular position in 1 patient and in an apical position
in 2 patients). None of the patients had phrenic nerve capture at the
ﬁnal lead position.
The paced QRS durationwas 156 ± 23 ms for the RVA group and
tended to be higher for the LVA group at 167 ± 22 ms (P ¼ 0.22).
Full datasets were available for all patients at 6 months and for
33 patients (15 and 18 patients in the RVA and LVA groups
respectively) at 12 months. There was no difference in the primary
endpoint of LVEF between the groups at 12 months: 60.4 ± 7.1% vs
62.1 ± 7.2% for the RVA and LVA groups respectively (difference
1.7%, 95%CI -1.8 to 5.2, P ¼ 0.26, see Fig. 2). After conservative
imputation, the difference was 0.7% (95%CI -4.1 to 5.5). None of the
echographic parameters (left ventricular remodelling, left ventric-
ular diastolic function, right ventricular systolic function, tricuspid
and mitral regurgitation etc.) showed any differences between or
Table 1
Patient demographics at baseline.
RVA (n ¼ 17) LVA (n ¼ 19) P
Age (yrs) 75.5 ± 5.3 75.3 ± 11.0 0.29
Male 12 9 0.48
Syncope 4 6 0.72
Atrial arrhythmias 1.00
Chronic AF 3 4
Paroxysmal AF/ﬂutter 4 2
Indication 0.95
Sinus dysfunction 4 2
AVB I 1 1
AVB II 5 6
AVB III 4 6
Slow AF 3 4
Comorbidities
Hypertension 4 3 0.68
Ischemic heart disease 2 2 1.00
Diabetes 5 7 0.73
Renal dysfunction 4 1 0.17
Previous stroke 1 2 1.00
Previous neoplasia 3 2 0.65
Pacemaker type
single/dual chamber 3/14 4/15 0.66
Medication
ACEI 4 5 1.00
ARB 3 4 1.00
CCB 4 7 0.48
Digoxin 1 1 1.00
Diuretics 6 8 0.74
Nitrates 0 1 1.00
Baseline echography
LVEF (%) 62.3 ± 8.3 62.6 ± 6.5 0.84
LVEDV (ml) 72.8 ± 23.5 65.4 ± 19.4 0.43
LVESV (ml) 28.2 ± 13.2 25.1 ± 11.0 0.51
AF ¼ atrial ﬁbrillation; ACEI ¼ angiotensinogen converting enzyme inhibitor;
ARB ¼ angiotensin receptor blockers; AVB ¼ atrioventricular block; CCB ¼ calcium
channel blockers; LVEF ¼ left ventricular ejection fraction; LVEDV ¼ left ventricular
end-diastolic volume; LVESV ¼ left ventricular systolic volume.
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within the groups over time (see Table 2). Electrical parameters
showed a signiﬁcantly higher ventricular capture threshold in the
LVA group (although values were comparable at 12 months) and
lower sensing amplitudes (see Table 3).
Procedure- or device-related adverse events occurred in 7 pa-
tients who had been randomized to the LV group: 2 CS dissections
(1 with pericardial effusion treated conservatively) and 1 pneu-
mothorax (these 3 patients received a right ventricular lead), 2
acute pericarditis treated conservatively (both patients had atrial
active-ﬁxation leads which were held responsible for the compli-
cation), 2 patients with loss of left ventricular capture at 6 months'
follow-up and 35 months after implantation. In the former case the
patient no longer required ventricular pacing and declined revision,
and in the latter patient a right ventricular lead had to be implanted
due to complete loss of capture. Sensing thresholds and lead im-
pedances were normal in both cases, without visible lead
dislodgement. There were 2 admissions for heart failure in patients
randomized to the RVA group, both were resolved with medical
treatment. None of the patients died during the study.
4. Discussion
The RIVELA study is the ﬁrst trial randomizing RVA to LVA for
anti-bradycardia pacing in patients with preserved ventricular
function. The main ﬁndings of our study were that 1) left uni-
ventricular pacing via a CS tributary was comparable to tradi-
tional RVA pacing in terms of LVEF and secondary cardiac functional
endpoints (left ventricular diastolic function and remodelling, right
ventricular systolic function, mitral/tricuspid valve function) at 1-
year follow-up 2) LVEF remained preserved in both groups over
follow-up as compared to baseline 3) the rate of cross-over from
LVA to RVA pacing at implantationwas high, mainly due to elevated
thresholds 4) there were signiﬁcantly higher capture thresholds
and lower sensing amplitudes with LVA pacing (although values
were on average acceptable), with instances of unexpected loss of
capture over follow-up.
The reports which showed superiority of LVA pacing compared
to RV pacing were acute hemodynamic studies using surgically-
placed epicardial leads in dogs [8,9] or in a pediatric population
[8], and may not reﬂect mid-term results in an adult population.
However, only 4/19 (21%) patients who were in the LVA group
actually received pacing from the apical region of the left ventricle,
with the majority receiving left ventricular pacing from a mid-
ventricular position due to CS tributary anatomy or were crossed
over to RVA pacing at implantation for technical reasons. It is
therefore impossible to draw deﬁnite conclusions on the effect of
LVA pacing from our dataset. Nevertheless, our study shows that
left univentricular pacing is feasible and that ventricular function is
preserved over follow-up, making this an option to consider in
selected patients, e.g. in case of a prosthetic tricuspid valve [15].
However, the implant procedure is more challenging thanwith RVA
pacing, with longer procedure durations and greater ﬂuoroscopic
exposure. The 42% crossover rate from LVA to RVA was mainly due
to high ventricular capture thresholds. CS leads are usually
implanted with a success rate of >95% in the setting of cardiac
resynchronization therapy, where higher thresholds may be
Fig. 2. Primary endpoint of left ventricular ejection fraction (LVEF) measured by 3D
echocardiography at 1 year. Data are mean ± SD. There were no difference between
groups at baseline, 6-month and 12 month follow-up, nor within each group over the
different timepoints. LVA ¼ left ventricular apex; RVA ¼ right ventricular apex.
Table 2
Comparison of echocardiographic parameters over time.
Baseline 6 months 12 months P
RVA LVA RVA LVA RVA LVA
LVEF (%) 62.3 ± 8.3 62.6 ± 6.5 60.2 ± 7.1 60.8 ± 8.9 60.5 ± 7.1 62.1 ± 7.2 0.59
LVEDV (ml) 72.8 ± 23.5 65.4 ± 19.4 85.9 ± 33.5 72.6 ± 27.9 81 ± 25 72 ± 25 0.77
LVESV (ml) 28.2 ± 13.2 25.1 ± 11.0 36.0 ± 20.9 30.2 ± 19.7 32.6 ± 14.1 28.1 ± 15.4 0.80
LVEDD (mm) 48.5 ± 6.5 46.4 ± 6.8 47.5 ± 6.3 47.5 ± 6.3 46 ± 6.6 45.9 ± 7.6 0.16
LVESD (mm) 30.8 ± 5.9 30.9 ± 6.2 32.6 ± 6.6 30.3 ± 7.6 30.5 ± 6.2 28.6 ± 6.0 0.67
LVFS (%) 36.6 ± 8.4 36.0 ± 7.5 32.4 ± 8.8 33.9 ± 11.7 33.7 ± 8.1 35.5 ± 9.1 0.77
LVPS base (%) 21.3 ± 7.1 19.9 ± 8.5 21.5 ± 9.1 25.5 ± 7.3 22 ± 5.1 24.8 ± 11.7 0.78
LVPS mid (%) 27.1 ± 8.4 29.6 ± 17.4 22.3 ± 7.8 26.2 ± 9.3 20.3 ± 12.2 18.1 ± 12.5 0.23
LVPS apex (%) 16.4 ± 8.2 22.5 ± 7.5 22.3 ± 9.8 21.0 ± 11.0 15.5 ± 17.2 22.3 ± 6.2 0.47
RVFAC (%) 48.1 ± 10.6 46.4 ± 6.8 41.5 ± 9.3 41.7 ± 7.0 42.2 ± 8.1 43.3 ± 8.9 0.70
TAPSE (mm) 19.1 ± 5.4 20.7 ± 4.9 19.0 ± 5.6 19.33 ± 4.0 17.9 ± 4.1 19.4 ± 2.9 0.30
TA TDI (cm/s) 12.2 ± 4.0 13.0 ± 3.2 11.1 ± 3.6 11.8 ± 2.4 11.0 ± 2.8 11.6 ± 2.2 0.13
PASPG (mmHg) 30.0 ± 13.1 23.2 ± 4.4 30.1 ± 12.4 25.8 ± 8.6 27.2 ± 7.1 26.8 ± 3.9 0.58
E/e’ lateral 10.0 ± 4.3 9.1 ± 4.1 11.4 ± 3.9 9.5 ± 4.1 11.0 ± 5.3 9.0 ± 3.6 0.57
E/e’ septal 15.3 ± 6.0 11.4 ± 4.6 14 ± 6.1 14.0 ± 5.3 12.6 ± 5.0 13.0 ± 4.6 0.54
E/e’ average 12.4 ± 4.8 10.3 ± 4.0 12.8 ± 4.5 11.5 ± 4.6 11.8 ± 4.9 11.1 ± 3.8 0.77
LAS (cm2) 21.3 ± 6.9 20.3 ± 5.0 22.1 ± 6.7 23.5 ± 14.2 20.8 ± 7.1 25.5 ± 18.9 0.76
Grade 3/4 MR (%) 29 26 35 16 29 21 0.71
Grade 3/4 TR (%) 29 11 35 26 29 42 0.18
LVEF ¼ left ventricular ejection fraction; LVEDV ¼ left ventricular end-diastolic volume; LVESV ¼ left ventricular end-systolic volume; LVEDD ¼ left ventricular end-diastolic
dimension; LVFS ¼ left ventricular fractional shortening; LVPS ¼ left ventricular peak 2D strain; RVAC ¼ right ventricular fractional area change; TAPSE ¼ tricuspid annulus
peak systolic excursion; TA TDI¼ tricuspid annulus tissue Doppler imaging peak velocity; PAPSG¼ pulmonary artery peak systolic pressure gradient; E/e’ average¼ average of
septal and lateral mitral E/e’; LAS ¼ left atrial surface in the apical 4 chamber view; MR ¼ mitral regurgitation; TR ¼ tricuspid regurgitation.
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accepted for treating heart failure. The indication for device im-
plantation in our study was anti-bradycardia pacing, where asys-
tole may result from loss of capture. This explains why a right
ventricular lead was preferred to provide reliable pacing in case of
high left ventricular capture thresholds. It may also be that CS lead
implantation in the setting of preserved ventricular function
without elevated right heart pressuresmay bemore difﬁcult, due to
less dilation of tributary veins and smaller hearts (although this
was not speciﬁcally evaluated). Electrical parameters were satis-
factory overall in both groups, and there were no instances of
evident ventricular lead dislodgment. Nevertheless, two patients in
the LVA group had unexpected complete loss of ventricular capture
(possibly due to micro-dislodgment), which casts a doubt on the
reliability of this option in patients requiring ventricular pacing.
In the quest for alternative pacing sites to the RVA, pacing of the
right interventricular septum has been explored, without conclu-
sive results. More recently, left ventricular septal pacing using an
investigational lead with a long electrically-active screw placed
deep in the interventricular septum has shown promising results
[16]. Also, there has lately been a revival in interest in His bundle
pacing which is the most physiological means to electrically acti-
vate the ventricles [17].
4.1. Study limitations
The main limitation of our study is its small sample size. The
crossover rate to right ventricular pacing in the LVA groupwas high,
mitigating possible differences between the groups. Most patients
who received a CS lead were paced from a mid-ventricular site
(rather than from the apex), which may have impacted cardiac
function. Follow-upwas limited to 1 year, whichmay have been too
short to show differences between treatment modalities. The pa-
tients were paced on average 67e83% of the time, and results may
have differed had they been paced permanently.
5. Conclusions
Pacing of the left ventricle via a CS tributary is an alternative to
RVA pacing and shows comparable outcome in terms of cardiac
function over 1 year follow-up in patients with preserved baseline
ventricular function. This is an option to consider in selected pa-
tients, e.g. those with prior tricuspid valve surgery, but does not
otherwise seem to confer any advantage compared to conventional
right ventricular pacing, with a more complex intervention and less
reliable electrical parameters.
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Table 3
Comparison of electrical parameters over time.
Baseline 6 months 12 months P
RV LV RV LV RV LV
V pacing (%) 77.0 ± 37.7 83.4 ± 32.4 82.3 ± 26.0 66.7 ± 38.8 69.4 ± 37.8 72.6 ± 39.0 0.32
V Capture threshold (V) 0.53 ± 0.16 0.86 ± 0.70 0.63 ± 0.24 0.92 ± 0.66 0.72 ± 0.21 0.72 ± 0.34 0.035
V impedance (Ohms) 597 ± 116 633 ± 150 550 ± 130 501 ± 84 539 ± 125 541 ± 170 0.41
V sensing (mV) 10.0 ± 3.1 9.2 ± 3.6 10.4 ± 2.1 7.4 ± 3.3 10.3 ± 3.3 7.7 ± 4.1 0.007
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